Published online before print March 10, 2003, doi: 10.1161/01.CIR.0000061911.47710.8A
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;107:1359.)
© 2003 American Heart Association, Inc.
Clinical Investigation and Reports |
The VIVA Trial
Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis
From the Divisions of Cardiology at Hennepin County Medical Center and University of Minnesota, Minneapolis (T.D.H.); Duke University Medical Center and Durham Veterans Affair Medical Center, Durham, NC (B.H.A.); Rhode Island Hospital, Brown Medical School, Providence (G.R.M.); University of Connecticut Medical Center, Farmington (M.A.A.); University of Iowa, Iowa City (J.J.L.); University of California, San Diego Medical Center (F.J.G.); Cedars-Sinai Medical Center, Los Angeles, Calif (P.K.S., D.S.B.); University of Texas, Houston (J.T.W.); University of Alabama, Birmingham (R.L.B.); TIMI Data Coordinating Center, Boston, Mass (C.M.G.); and Genentech, Inc, South San Francisco, Calif (A.B., A.C.R., J.F., E.R.M.).
Reprint requests to Timothy D. Henry, MD, Minneapolis Heart Institute Foundation, 920 E 28th St, Ste 40, Minneapolis, MN 55407. E-mail henry003{at}tc.umn.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionAppendix 1References |
|---|
Background— Recombinant human vascular endothelial growth factor protein (rhVEGF) stimulates angiogenesis in animal models and was well tolerated in Phase I clinical trials. VIVA (Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis) is a double-blind, placebo-controlled trial designed to evaluate the safety and efficacy of intracoronary and intravenous infusions of rhVEGF.
Methods and Results— A total of 178 patients with stable exertional angina, unsuitable for standard revascularization, were randomized to receive placebo, low-dose rhVEGF (17 ng · kg-1 · min-1), or high-dose rhVEGF (50 ng · kg-1 · min-1) by intracoronary infusion on day 0, followed by intravenous infusions on days 3, 6, and 9. Exercise treadmill tests, angina class, and quality of life assessments were performed at baseline, day 60, and day 120. Myocardial perfusion imaging was performed at baseline and day 60. At day 60, the change in exercise treadmill test (ETT) time from baseline was not different between groups (placebo, +48 seconds; low dose, +30 seconds; high dose, +30 seconds). Angina class and quality of life were significantly improved within each group, with no difference between groups. By day 120, placebo-treated patients demonstrated reduced benefit in all three measures, with no significant difference compared with low-dose rhVEGF. In contrast, high-dose rhVEGF resulted in significant improvement in angina class (P=0.05) and nonsignificant trends in ETT time (P=0.15) and angina frequency (P=0.09) as compared with placebo.
Conclusions— rhVEGF seems to be safe and well tolerated. rhVEGF offered no improvement beyond placebo in all measurements by day 60. By day 120, high-dose rhVEGF resulted in significant improvement in angina and favorable trends in ETT time and angina frequency.
Key Words: angiogenesis • growth substances • ischemia • angina • heart disease
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionAppendix 1References |
|---|
Angiogenesis is the growth and proliferation of new blood vessels from existing vasculature. The use of angiogenic growth factors to promote the growth of collateral blood vessels in ischemic tissue has been termed therapeutic angiogenesis. Vascular endothelial growth factor (VEGF) is a family of angiogenic growth factors specific for endothelial cells.1,2 Successful therapeutic angiogenesis has been reported with VEGF protein or genes that encode VEGF in preclinical models.3–8 Initial clinical trials in patients with myocardial ischemia9–16 and peripheral vascular disease17 have been encouraging but have enrolled small numbers of patients, and few had placebo controls. Three recent double-blind, placebo-controlled trials utilizing intracoronary fibroblast growth factor (FGF)-2 protein,18 intracoronary adenovirus encoding FGF-4,19 and intramyocardial plasmid encoding VEGF-220 demonstrated modest clinical benefits.
Initial clinical trials using intracoronary9,10 and intravenous2 recombinant VEGF165 protein (rhVEGF) demonstrated safety, tolerability, and encouraging clinical results. These trials led to the VIVA trial (Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis), a double-blind, placebo-controlled trial designed to determine the safety and efficacy of intracoronary and intravenous rhVEGF for therapeutic angiogenesis in patients with chronic myocardial ischemia not amenable to standard revascularization techniques.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionAppendix 1References |
|---|
Patients
The study was reviewed by the appropriate institutional review boards and was conducted in accordance with the Helsinki Declaration of 1975 (revised 1983). Eligible patients were 40 to 75 years of age with stable exertional angina and areas of viable but underperfused myocardium according to perfusion imaging, who were judged unsuitable for revascularization on the basis of coronary angiography within the previous 6 months. Patients were required to exercise between 3 and 11 minutes on an exercise treadmill test (ETT). Exclusion criteria included unstable angina, myocardial infarction or CABG within the previous 6 months, PCI within the previous 3 months, previous myocardial laser revascularization or angiogenic growth factor treatment, ejection fraction <25%, pregnancy, history of cancer within the previous 5 years, proliferative retinopathy or macular degeneration, renal insufficiency, or other severe concurrent illness.
Study Procedures
Clinical evaluations, blood chemistries, and quality of life (QOL) assessments (Seattle Angina Questionnaire [SAQ], the Short Form-36 [SF-36] and the Duke Activity Scale Index [DASI]) were completed at baseline, day 60, and day 120. Retinal photographs were obtained at baseline and day 120. Patients underwent an ETT with myocardial perfusion imaging at baseline and day 60 (±4), and without imaging at day 120 (±5). Medications were kept constant throughout the treatment period.
Treatment Regimen
Patients were randomized to receive a 20-minute intracoronary infusion of placebo, low-dose rhVEGF (17 ng · kg-1 · min-1), or high-dose rhVEGF (50 ng · kg-1 · min-1) followed by 4-hour intravenous infusion on days 3, 6, and 9.
Myocardial Perfusion Imaging
The protocol consisted of a rest thallium-201 scan and gated rest technicium-99 m-sestamibi scan followed by a nongated redistribution thallium-201 scan and a gated stress sestamibi on day 2. A modified Bruce protocol to maximal exercise off medications (ß-blockers held >24 hours) was utilized with day-60 injection of sestamibi at the same heart rate as the baseline ETT to assess myocardial perfusion at a similar workload. Summed stress and rest scores were calculated according to a 20-segment model (range from 0 [normal activity] to 4 [no activity]).
Statistical Analysis
The primary end point of the study was change in ETT time from baseline to day 60 between groups. Secondary end points included change in ETT time from baseline to day 120, rest and exercise myocardial perfusion imaging on day 60, and angina class and QOL measurements at days 60 and 120.
Primary analysis was based on intention to treat. Patients who died or were lost to follow-up were assigned least rank in the ETT analysis, and groups were compared with the Wilcoxon rank-sum test. Because the change in ETT time was not normally distributed, median values were used. Analysis for changes in angina class was performed by using an exact linear-by-linear association test with no adjustment for the 2 patients who died. Statistical analysis was performed with the use of SAS statistical software. All statistical tests were two-sided and conducted at the 0.05 level of significance.
The sample size estimate for the primary end point of change in ETT time was based on previous studies in similar populations. Assuming a change in ETT time of 2 minutes with a standard deviation of 3.3 minutes, a sample size of 50 subjects in each of three groups would provide 90% power to detect a 2-minute difference between treatment and placebo equivalent at the 0.05 level of significance.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionAppendix 1References |
|---|
Baseline Characteristics
A total of 178 subjects were enrolled at 33 trial sites (see Appendix) from April through December 1998. Sixty-three patients received placebo, 56 patients low-dose (17 ng · kg-1 · min-1) rhVEGF, and 59 patients high-dose (50 ng · kg-1 · min-1) rhVEGF. Baseline characteristics are shown in Table 1. There were no significant differences between the three groups. As expected, there was a high frequency of previous myocardial infarction, revascularization, and use of cardiovascular medications in this cohort of patients. More patients receiving high-dose rhVEGF had diabetes (39%) compared with the placebo group (30%) (P=0.30).
|
Safety and Tolerability
Infusion of rhVEGF was well tolerated by all groups. The maximal percent decrease in systolic blood pressure with each infusion is shown in Table 2. Although the decrease in systolic blood pressure was greater in rhVEGF-treated patients, the changes were modest and transient, and only 1 patient (high-dose group) had severe hypotension (chest pain with systolic pressure <100 mm Hg, which resolved with hydration).
|
In previous trials, a flushing reaction was noted. In VIVA, flushing occurred at least once in 35% of placebo patients, 74% of the low-dose patients, and 90% of the high-dose patients.
There were no clinically significant changes from baseline within or between groups in serum electrolytes, chemistries, hematologic parameters, or urinalysis. In addition, there was no increase in adverse events in rhVEGF-treated patients, including thrombocytopenia, proteinuria or renal insufficiency, allergic reactions, worsening of congestive heart failure, pleural effusions, or pedal edema.
Clinical Events
Overall, there was no difference in clinical event rates across all three groups during the 120-day study period (Table 3). Two deaths occurred, both in the placebo group. Despite careful baseline screening, 3 patients were diagnosed with new cancers, all in the placebo group. One patient in the placebo group developed severe myocardial ischemia with cardiogenic shock on day 7. Only 1 patient (placebo treated with preexisting diabetes) developed macular edema.
|
Exercise Results
The baseline exercise duration was similar between the three groups: placebo group, 7.8±2.8 minutes; low-dose group, 7.7±2.2 minutes; and high-dose group, 7.6±2.5 minutes. The median change from baseline with individual data is shown in Figure 1. There was no evidence of a treatment effect on the primary end point, change in ETT time from baseline to day 60. From day 60 to day 120, the median change in ETT time declined from 48 to 24 and 30 to 18 seconds in the placebo and low-dose rhVEGF patients, respectively. In contrast, high-dose rhVEGF-treated patients improved from 30 seconds at day 60 to 48 seconds at day 120, a significant improvement from baseline (P=0.01). This resulted in a favorable trend at day 120 in high-dose rhVEGF-treated patients compared with placebo (48 versus 24 seconds, P=0.15) (Figure 2).
|
|
1 class improvement), and angina frequency (change in SAQ score). *P=0.05, **P=0.09, 
P=0.15, all high dose vs placebo. PL indicates placebo; LD, low dose; and HD, high dose.
Angina/Quality of Life
The distribution of Canadian Class angina at baseline is shown in Figure 3A. The mean angina class at baseline was 2.8±0.7 in the placebo group, 2.6±0.8 in the low-dose rhVEGF-treated group, and 2.6±0.9 in the high-dose rhVEGF-treated group. Complete follow-up data were achieved in all but 3 patients (2 deaths). Although all three groups demonstrated a significant improvement in angina class from baseline to day 60, there was no significant difference between groups (Figure 3B). As with ETT time, there was a loss of benefit in placebo patients from days 60 to 120, with ongoing improvement in high-dose rhVEGF-treated patients. This resulted in a significant improvement in angina class for high-dose rhVEGF-treated patients compared with placebo at day 120 (P=0.05) (Figures 2 and 3C). The mean angina class for placebo, low-dose rhVEGF, and high-dose rhVEGF was 2.0±0.8, 1.9±0.8, and 1.8±0.9 at day 60 and 2.1±1.0, 1.8±0.8, and 1.6±0.9 at day 120, respectively.
|
Clinically significant improvements were seen in all 3 groups for all 5 domains of the SAQ at day 60, but there was no significant difference between groups. The most striking improvements were seen in angina stability and angina frequency. Similar findings were seen for the SF-36 assessment of physical function and the DASI. As with ETT time and angina class, there was less benefit in placebo patients at day 120 and ongoing improvement in the high-dose rhVEGF group. The changes from baseline to day 60 and to day 120 for the angina frequency domain of the SAQ are shown in Figure 3 (day-120 placebo versus high-dose rhVEGF, P=0.09). At day 120, physical function on SF-36 was improved in the high-dose rhVEGF patients compared with placebo (P<0.05).
Myocardial Perfusion
Myocardial perfusion at stress, rest, and redistribution was performed to assess areas of viable, infarcted, ischemic, and hibernating myocardium. No significant improvement was seen in the summed rest or summed stress scores at day 60 (Table 4). Likewise, there was no significant improvement in the resting or post-stress ejection fraction.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionAppendix 1References |
|---|
The VIVA trial is the first randomized, double-blind, placebo-controlled trial using rhVEGF for therapeutic angiogenesis. The primary end point of the trial, change in ETT time from baseline to day 60, was negative. At day 60, all three groups had improvements from baseline in angina class and QOL measurements, but there was no significant difference between groups. At day 120, there was less benefit in the placebo group and ongoing improvement in the high-dose rhVEGF-treated patients, resulting in a significant improvement in angina class at day 120 as well as favorable trends for ETT time and QOL. This may suggest a dose-dependent effect of rhVEGF. rhVEGF seems to be well tolerated, with excellent short-term safety. Results of this trial have important implications for the design of subsequent trials in the field of therapeutic angiogenesis.
Previous Trials of Coronary Angiogenesis
Initial angiogenic growth factor trials generated considerable excitement with regard to therapeutic angiogenesis for patients with severe myocardial ischemia not amenable to revascularization. Encouraging clinical results were reported in small trials (without control patients) using intramyocardial gene therapy with a plasmid encoding VEGF165,12 an adenovirus encoding VEGF121,13 and intracoronary FGF-2 protein.15 Two small trials using FGF protein in conjunction with CABG11,14 suggested clinical benefits. Recently, three double-blind, placebo-controlled clinical trials using intracoronary FGF-2 protein, intracoronary FGF-4 gene therapy, and intramyocardial VEGF-2 gene therapy have reported excellent short-term safety with modest clinical benefits, especially in particular patient subgroups.18–20 Despite these promising initial results, the long-term efficacy and safety of angiogenic growth factors need to be established in large placebo-controlled trials.
Previous Trials With rhVEGF
In the initial experience with rhVEGF, 15 patients received 20-minute intracoronary infusions (5, 17, 50, or 167 ng · kg-1 · min-1).9 The maximum tolerated dose was identified as 50 ng · kg-1 · min-1 with a decrease in blood pressure at the 167-ng · kg-1 · min-1 dose. Although there was no change in the summed stress score, at day 60 there was a significant improvement in the summed rest score in the high-dose VEGF group at 14.7 versus 10.7 (P<0.05).10 All 7 patients with follow-up angiograms had a significant improvement in collateral density score. In addition, 13 of the 15 patients had a significant decrease in angina class (P=0.002).
In a second trial, 28 patients received intravenous rhVEGF (17 to 100 ng · kg-1 · min-1 for 1 to 4 hours).2 As in the intracoronary trial, 50 ng · kg-1 · min-1 was the maximally tolerated dose, on the basis of the decrease in systolic pressure with 100 ng · kg-1 · min-1. Myocardial perfusion imaging improved in at least 2 segments by 2 perfusion grades in 54% of patients and was more impressive in resting perfusion, as with the intracoronary trial. More collaterals were seen in 38% of patients at 60-day angiographic follow-up. In both trials, rhVEGF165 was well tolerated with no significant adverse events.
Safety
Concern exists about pathological angiogenesis, such as accelerated growth of malignant tumors, retinopathy, or progression of atherosclerosis, with the use of angiogenic growth factors. Results of this trial indicate excellent short-term safety with rhVEGF165. Both infusions were well tolerated, with only one episode of severe hypotension and no other acute adverse events. No patient treated with rhVEGF developed cancer or ophthalmological abnormalities. There was no evidence for progression of atherosclerosis by angiography and no deaths or myocardial infarctions in patients treated with rhVEGF. Further assurances of safety will require a larger number of patients treated with a longer-term follow-up, but these results are encouraging as we identify the ideal target population and develop methods to improve efficacy.
Efficacy
The primary end point of the trial, powered to detect a 2-minute improvement in rhVEGF-treated patients compared with placebo, was negative. At day 120, the improvement in ETT time was 48 seconds for 50 ng · kg-1 · min-1 rhVEGF compared with 24 seconds for placebo patients. These increases are modest in comparison to previous Phase I trials without placebo control groups. For example, Laham et al15 reported a 123-second improvement in ETT time at day 180 with intracoronary FGF-2 protein, and Symes et al12 reported a 170-second improvement at day 180 with intramyocardial plasmid encoding VEGF165.
Angina measured by angina class and angina frequency on the SAQ was significantly improved in all 3 groups at day 60, but the difference between groups was not statistically significant. As with ETT time, the benefit in the placebo group was diminished at day 120 for both angina class and angina frequency. At the same time, the high-dose rhVEGF-treated patients continued to improve from days 60 to 120. This resulted in a significant improvement in angina class at day 120 (P=0.05), a prespecified secondary end point. Angina frequency as reported by SAQ was consistent with the results of angina class, with a favorable trend (P=0.09) toward improvement at day 120. The improvement in angina frequency for high-dose rhVEGF patients at day 120 was 23, only slightly less than results with PTCA.21
At day 120, 45% of high-dose rhVEGF-treated patients had class 0 to 1 angina, compared with 23% of placebo-treated patients. Likewise, the number of patients who had class 3 or 4 angina in the placebo group was double that of the patients treated with high-dose VEGF (35% versus 15%).
In contrast to uncontrolled Phase I trials, there were no improvements in myocardial perfusion at day 60. The summed rest score in VIVA was 5.9 compared with 14.7 in the Phase I trial for patients treated with 50 ng · kg-1 · min-1, perhaps indicating a healthier patient population. If the predominant benefit of angiogenic therapy is seen in patients with resting perfusion defects, as previously reported,10 this may explain the lack of benefits seen at day 60. A modest increase in collateral blood flow may be insufficient to prevent ischemia at peak exercise off ß-blockers as performed in this trial. Unfortunately, myocardial perfusion imaging was not performed at day 120; therefore, it is unknown whether the improvements noted at day 120 in the high-dose rhVEGF-treated patients were associated with changes in myocardial perfusion.
Placebo Effect
An important finding of this trial is the prominent placebo effect noted at day 60 with a 48-second improvement in ETT time, 56% of patients improving at least one angina class, and a nearly 14-point improvement in SAQ angina frequency domain. Although these benefits were diminished at day 120, 47% of patients had a persistent improvement in angina class. To the best of our knowledge, there were no changes in medical therapy or smoking status during the course of the trial, and only 1 placebo patient underwent revascularization.
Although the improvement noted in the placebo group emphasizes the need for caution in the interpretation of positive results of uncontrolled trials, the adverse events in the placebo group serve to highlight another critical aspect of placebo-controlled trials. Despite extensive baseline screening, 3 patients in the placebo group developed cancer over the course of the 120-day trial. Likewise, the only 2 deaths and the only ophthalmological changes occurred in placebo patients. This clearly illustrates the importance of a placebo group in interpretation of both positive and negative results.
Time Course of Angiogenesis
The patients treated with 50 ng · kg-1 · min-1 of rhVEGF demonstrated an improvement in ETT time, angina class, and SAQ angina frequency from day 60 to 120. Although successful angiogenesis has been demonstrated in preclinical models, these have, in general, been short-term models, and little is known about the long-term efficacy of angiogenic growth factors. One trial in a porcine model using intravenous rhVEGF demonstrated a significant improvement in myocardial function at 6 months compared with 3 months.22 The ongoing improvement noted in the VIVA trial is similar to other trials with rhVEGF165; for example the plasmid-encoding VEGF165, with 33%, 44%, and 60% of patients free of angina at 2, 3, and 6 months, respectively.13
Explanation/Limitations
Despite the excellent safety profile of rhVEGF and an improvement in several secondary end points at day 120, these results are disappointing. Potential explanations include suboptimal dose or route of administration, a healthier population of patients enrolled, or lack of efficacy using this dose and route of administration of VEGF165 protein. The ideal end point and time points for assessment of benefit in therapeutic angiogenesis trials is still unclear. For example, time to angina or ST depression and the percentage of patients limited by angina were not prespecified end points in VIVA but may add insight into the ETT results. Finally, more preclinical data are needed with regard to the time course of angiogenesis, the ideal growth factor, and the optimal dose and route of administration.
Conclusion
In conclusion, intracoronary plus intravenous rhVEGF was well tolerated with excellent short-term safety. There was no evidence for a treatment effect on the primary end point, change in ETT time from baseline to day 60, and no improvements in myocardial perfusion. A prominent placebo effect was present at day 60 but was diminished by day 120. Patients treated with high-dose VEGF had a significant improvement in angina class at day 120. Although this is the first randomized, controlled trial of VEGF for therapeutic angiogenesis, it is still a relatively small trial with a short-term follow-up. Larger trials with longer-term follow-up are required to determine the long-term efficacy and safety of VEGF. Finally, trials using alternative growth factors, dose regimens, and methods of delivery, including sustained release and gene transfer, are needed to enhance the treatment benefit of angiogenic growth factors in patients with severe myocardial ischemia who are not optimal candidates for standard revascularization techniques.
|
Acknowledgments |
|---|
The authors received research grants for support of the VIVA trial from Genentech. Alex Bajamonde, Amy Chen Rundle, Jennifer Fine, and Edward R. McCluskey all are employees of Genentech.
|
Footnotes |
|---|
*The VIVA Investigators are listed in the Appendix.
Guest editor for this article was Carl J. Pepine, MD, from the University of Florida College of Medicine, Gainesville.
|
Appendix 1 |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionAppendix 1References |
|---|
Appendix
In addition to the authors, the following persons were members of the VIVA study group: Hennepin County Medical Center, Minneapolis, Minn, C. Boisjolie; Durham VA and Duke University, Durham, NC, D. Landis, C. Martz; Rhode Island Hospital, Providence, L. Donahue; University of Connecticut Health Center, Farmington, M.B. Barry; University of Iowa, Iowa City, M. Costigan; University of California San Diego, J. Van Dijk; Cedar-Sinai Medical Center, Los Angeles, Calif, M. Gheorghiu; Hermann Hospital, Houston, Tex, L. Weiglet; Mt Sinai, New York, NY, I. Guzman; Northwestern University, Chicago, Ill, R. Hendel, B. Toth; University of Alabama, Birmingham, C. Ritondo; University of California at Davis, R. Valente, B. Pierce; New England Medical Center, Boston, Mass, J. Smith, R. Miele; Prairie Heart Institute, Springfield, Ill, K. Rocha-Singh, K.S. Laswell; VA Hospital, Palo Alto, Calif, J. Giacomini, V. Sharma; Cleveland Clinic Heart Center, Ohio, S. Ellis, K. Comella; Minneapolis VA Medical Center, Minn, A. From, L. Bass; Stanford University School of Medicine, Palo Alto, Calif, J. Cooke, S. Rockson, L. Lissin; Texas Heart/St Luke’s, Houston, J. Willerson, M. Harlan; Baylor College, Houston, Tex, N. Kleiman, K. Maresh; Crawford Long Hospital of Emory University, Atlanta, Ga, J. Marshall, K. Moehring; Henry Ford Hospital, Detroit, Mich, P. Kraft, M. Fox; University of Southern California, Los Angeles, D. Faxon, I. Gutierrez; University of Virginia, Charlottesville, I. Sarembock, L. Snyder; Winthrop Hospital, Mineola, NY, R. Steingart, S. Parker; Arizona Heart Institute, R. Strumpf, S. Spooner; Atlanta VA, Ga, J. Marshall, A. Lane; Hartford Hospital, Hartford, Conn, J. Cloutier; MCO of Ohio, Toledo, D. Weisshaar, D. Stewart; Sequoia Hospital, Redwood City, Calif, T. Hinohara, M. Johnson; Genentech Inc, South San Francisco, Calif, C. Luce, T. Tu, D. Bisio, J. Kuczma; University of Wisconsin Ophthalmology Core Laboratory, R. Klein, M. Neider, S. Meuer; Perfuse Core Laboratory, K. Ryan; and Cedar-Sinai Nuclear Cardiology, H. Lewin, L. Miranda.
Received July 24, 2002; revision received November 13, 2002; accepted December 4, 2002.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionAppendix 1References |
|---|
1. Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol. 1999; 237: 1–30.[Medline] [Order article via Infotrieve]
2. Henry TD, Abraham JA. Review of preclinical and clinical results with vascular endothelial growth factor for therapeutic angiogenesis. Curr Int Card Rep. 2000; 2: 228–241.
3. Banai S, Jaklitsch MT, Shou M, et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation. 1994; 89: 2183–2189.
4. Pearlman JD, Hibberd MG, Chuang ML, et al. Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis. Nat Med. 1995; 1: 1085–1089.[CrossRef][Medline] [Order article via Infotrieve]
5. Harada K, Friedman M, Lopez JJ, et al. Vascular endothelial growth factor administration in chronic myocardial ischemia. Am J Physiol. 1996; 270(5 pt 2): H1791–H1802.
6. Lopez JJ, Laham RJ, Stamler A, et al. VEGF administration in chronic myocardial ischemia in pigs. Cardiovasc Res. 1998; 40: 272–281.
7. Hariawala MD, Horowitz JR, Esakof D, et al. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J Surg Res. 1996; 63: 77–82.[CrossRef][Medline] [Order article via Infotrieve]
8. Giordano FJ, Ross J, Peterson KL, et al. Intravenous or intracoronary VEGF ameliorates chronic myocardial ischemia. Circulation. 2000; 98 (suppl I): I-455.
9. Henry TD, Rocha-Singh K, Isner JM, et al. Results of intracoronary recombinant human vascular endothelial growth factor (rhVEGF) administration trial. Am Heart J. 2001; 142: 878–880.
10. Hendel RC, Henry TD, Rocha-Singh K, et al. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation. 2000; 101: 118–121.
11. Schumacher B, Pecher P, von Specht BU, et al. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation. 1998; 97: 645–650.
12. Symes J, Losordo D, Vale P, et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg. 1999; 68: 830–837.
13. Rosengart TK, Lee LY, Patel SR, et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation. 1999; 100: 468–474.
14. Laham RJ, Selke FW, Edelman ER, et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation. 1999; 100: 1865–1871.
15. Laham RJ, Chronos NA, Pike M, et al. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study. J Am Coll Cardiol. 2000; 36: 2132–2139.
16. Stegman TJ, Hoppert T, Schlurmann W, et al. First angiogenic treatment of coronary heart disease by FGF-1: long-term results after 3 years. CVR. 2000; 1: 5–10.
17. Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia [see comments]. Circulation. 1998; 97: 1114–1123.
18. Simons M, Annex BH, Laham RJ, et al. Pharmacologic treatment of coronary artery disease with recombinant fibroblast growth factor-2. Circulation. 2002; 105: 788–793.
19. Grines CL, Watkins MW, Helmer G, et al. Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris. Circulation. 2002; 105: 1291–1297.
20. Losordo DW, Vale PR, Hendel RC, et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation. 2002; 105: 2012–2018.
21. Spertus JA, Winder JA, Dewhurst TA, et al. Monitoring the quality of life in patients with coronary artery disease. J Am Coll Cardiol. 1994; 74: 1240–1244.
22. Biswas SS, Domkowski PW, Diodato LH, et al. Pharmacokinetic and efficacy of intravenous vascular endothelial growth factor (rhVEGF) in porcine hibernating myocardium. J Am Coll Cardiol. 2001; 37: 338A.
This article has been cited by other articles:
 |
|
 |
|
  H. Dong, Q. Wang, Y. Zhang, B. Jiang, X. Xu, and Z. Zhang Angiogenesis Induced by hVEGF165 Gene Controlled by Hypoxic Response Elements in Rabbit Ischemia Myocardium Experimental Biology and Medicine, December 1, 2009; 234(12): 1417 - 1424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kobulnik, M. A. Kuliszewski, D. J. Stewart, J. R. Lindner, and H. Leong-Poi Comparison of gene delivery techniques for therapeutic angiogenesis ultrasound-mediated destruction of carrier microbubbles versus direct intramuscular injection. J. Am. Coll. Cardiol., October 27, 2009; 54(18): 1735 - 1742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Facemire, A. B. Nixon, R. Griffiths, H. Hurwitz, and T. M. Coffman Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression Hypertension, September 1, 2009; 54(3): 652 - 658. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Hausenloy and D. M. Yellon Cardioprotective growth factors Cardiovasc Res, July 15, 2009; 83(2): 179 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Fujii, Z. Sun, S.-H. Li, J. Wu, S. Fazel, R. D. Weisel, H. Rakowski, J. Lindner, and R.-K. Li Ultrasound-Targeted Gene Delivery Induces Angiogenesis After a Myocardial Infarction in Mice J. Am. Coll. Cardiol. Img., July 1, 2009; 2(7): 869 - 879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. N. Le, C.-W. Hwang, A. R. Tzafriri, M. A. Lovich, A. Hayward, and E. R. Edelman Vascular Regeneration by Local Growth Factor Release Is Self-Limited by Microvascular Clearance Circulation, June 9, 2009; 119(22): 2928 - 2935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Lieb, R. Safa, E. J. Benjamin, V. Xanthakis, X. Yin, L. M. Sullivan, M. G. Larson, H. M. Smith, J. A. Vita, G. F. Mitchell, et al. Vascular endothelial growth factor, its soluble receptor, and hepatocyte growth factor: clinical and genetic correlates and association with vascular function Eur. Heart J., May 1, 2009; 30(9): 1121 - 1127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Izzedine, S. Ederhy, F. Goldwasser, J. C. Soria, G. Milano, A. Cohen, D. Khayat, and J. P. Spano Management of hypertension in angiogenesis inhibitor-treated patients Ann. Onc., May 1, 2009; 20(5): 807 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zhang, L. Ding, Y. Zhao, W. Sun, B. Chen, H. Lin, X. Wang, L. Zhang, B. Xu, and J. Dai Collagen-Targeting Vascular Endothelial Growth Factor Improves Cardiac Performance After Myocardial Infarction Circulation, April 7, 2009; 119(13): 1776 - 1784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S H Schirmer, F C van Nooijen, J J Piek, and N van Royen Stimulation of collateral artery growth: travelling further down the road to clinical application Heart, February 1, 2009; 95(3): 191 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Takenaka, M. Horiba, H. Ishiguro, A. Sumida, M. Hojo, A. Usui, T. Akita, S. Sakuma, Y. Ueda, I. Kodama, et al. Midkine prevents ventricular remodeling and improves long-term survival after myocardial infarction Am J Physiol Heart Circ Physiol, February 1, 2009; 296(2): H462 - H469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Birk, J. Barbato, L. Mureebe, and R. A. Chaer Basic Science Review: Current Insights on the Biology and Clinical Aspects of VEGF Regulation Vascular and Endovascular Surgery, January 1, 2009; 42(6): 517 - 530. [Abstract] [PDF]
|
|
|
|
 |
|
 M. C. van Oostrom, O. van Oostrom, P. H. A. Quax, M. C. Verhaar, and I. E. Hoefer Insights into mechanisms behind arteriogenesis: what does the future hold? J. Leukoc. Biol., December 1, 2008; 84(6): 1379 - 1391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Modarai, J. Humphries, J.A. Gossage, M. Waltham, K.G. Burnand, G.S. Kanaganayagam, A. Afuwape, E. Paleolog, A. Smith, and A. Wadoodi Adenovirus-Mediated VEGF Gene Therapy Enhances Venous Thrombus Recanalization and Resolution Arterioscler Thromb Vasc Biol, October 1, 2008; 28(10): 1753 - 1759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Huang, D. A. Chan, F. Jia, X. Xie, Z. Li, G. Hoyt, R. C. Robbins, X. Chen, A. J. Giaccia, and J. C. Wu Short Hairpin RNA Interference Therapy for Ischemic Heart Disease Circulation, September 30, 2008; 118(14_suppl_1): S226 - S233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Jay, B. R. Shepherd, J. P. Bertram, J. S. Pober, and W. M. Saltzman Engineering of multifunctional gels integrating highly efficient growth factor delivery with endothelial cell transplantation FASEB J, August 1, 2008; 22(8): 2949 - 2956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. C. Gurtner and E. Chang "Priming" Endothelial Progenitor Cells: A New Strategy to Improve Cell Based Therapeutics Arterioscler Thromb Vasc Biol, June 1, 2008; 28(6): 1034 - 1035. [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Schirmer, J. O. Fledderus, P. T.G. Bot, P. D. Moerland, I. E. Hoefer, J. Baan Jr, J. P.S. Henriques, R. J. van der Schaaf, M. M. Vis, A. J.G. Horrevoets, et al. Interferon-{beta} Signaling Is Enhanced in Patients With Insufficient Coronary Collateral Artery Development and Inhibits Arteriogenesis in Mice Circ. Res., May 23, 2008; 102(10): 1286 - 1294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. O. Curwen, H. L. Musgrove, J. Kendrew, G. H.P. Richmond, D. J. Ogilvie, and S. R. Wedge Inhibition of Vascular Endothelial Growth Factor-A Signaling Induces Hypertension: Examining the Effect of Cediranib (Recentin; AZD2171) Treatment on Blood Pressure in Rat and the Use of Concomitant Antihypertensive Therapy Clin. Cancer Res., May 15, 2008; 14(10): 3124 - 3131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-J. Mourad, G. des Guetz, H. Debbabi, and B. I. Levy Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation Ann. Onc., May 1, 2008; 19(5): 927 - 934. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Higuchi, F. M. Bengel, S. Seidl, P. Watzlowik, H. Kessler, R. Hegenloh, S. Reder, S. G. Nekolla, H. J. Wester, and M. Schwaiger Assessment of {alpha}v{beta}3 integrin expression after myocardial infarction by positron emission tomography Cardiovasc Res, May 1, 2008; 78(2): 395 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Saueressig, A. M. Neto, E. A.F. Fortis, D. Westphal, M. I.A. Edelweiss, L. Meurer, and U. Matte Vascular endothelial growth factor gene therapy induces early re-establishment of canine bronchial circulation Eur. J. Cardiothorac. Surg., April 1, 2008; 33(4): 717 - 722. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. L. Johnson, L. Schofield, T. Donahay, M. Bouchard, A. Poppas, and R. Haubner Radiolabeled RGD Peptides to Image Angiogenesis in Swine Model of Hibernating Myocardium. J. Am. Coll. Cardiol. Img., January 1, 2008; 1: 500 - 510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Horvath and Y. Zhou Transmyocardial Laser Revascularization and Extravascular Angiogenetic Techniques to Increase Myocardial Blood Flow Card. Surg. Adult, January 1, 2008; 3(2008): 733 - 752. [Full Text]
|
|
|
|
|
|
P. Voisine, A. Rosinberg, J. J. Wykrzykowska, Y. Shamis, G. F. Wu, E. Appelbaum, J. Li, F. W. Sellke, D. Pinto, C. M. Gibson, et al. Skin-derived microorgan autotransplantation as a novel approach for therapeutic angiogenesis Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H213 - H219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Rophael, R. O. Craft, J. A. Palmer, A. J. Hussey, G. P.L. Thomas, W. A. Morrison, A. J. Penington, and G. M. Mitchell Angiogenic Growth Factor Synergism in a Murine Tissue Engineering Model of Angiogenesis and Adipogenesis Am. J. Pathol., December 1, 2007; 171(6): 2048 - 2057. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Widakowich, G. de Castro Jr., E. de Azambuja, P. Dinh, and A. Awada Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers Oncologist, December 1, 2007; 12(12): 1443 - 1455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hazarika, A. O. Dokun, Y. Li, A. S. Popel, C. D. Kontos, and B. H. Annex Impaired Angiogenesis After Hindlimb Ischemia in Type 2 Diabetes Mellitus: Differential Regulation of Vascular Endothelial Growth Factor Receptor 1 and Soluble Vascular Endothelial Growth Factor Receptor 1 Circ. Res., October 26, 2007; 101(9): 948 - 956. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-W. Cho, I.-K. Kim, S. H. Bhang, B. Joung, Y. J. Kim, K. J. Yoo, Y.-S. Yang, C. Y. Choi, and B.-S. Kim Combined therapy with human cord blood cell transplantation and basic fibroblast growth factor delivery for treatment of myocardial infarction Eur J Heart Fail, October 1, 2007; 9(10): 974 - 985. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Tritsaris, M. Myren, S. B. Ditlev, M. V. Hubschmann, I. van der Blom, A. J. Hansen, U. B. Olsen, R. Cao, J. Zhang, T. Jia, et al. IL-20 is an arteriogenic cytokine that remodels collateral networks and improves functions of ischemic hind limbs PNAS, September 25, 2007; 104(39): 15364 - 15369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. D. Henry, C. L. Grines, M. W. Watkins, N. Dib, G. Barbeau, R. Moreadith, T. Andrasfay, and R. L. Engler Effects of Ad5FGF-4 in Patients With Angina: An Analysis of Pooled Data From the AGENT-3 and AGENT-4 Trials J. Am. Coll. Cardiol., September 11, 2007; 50(11): 1038 - 1046. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Mees, S. Wagner, E. Ninci, S. Tribulova, S. Martin, R. van Haperen, S. Kostin, M. Heil, R. de Crom, and W. Schaper Endothelial Nitric Oxide Synthase Activity Is Essential for Vasodilation During Blood Flow Recovery but not for Arteriogenesis Arterioscler Thromb Vasc Biol, September 1, 2007; 27(9): 1926 - 1933. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Leong-Poi, M. A. Kuliszewski, M. Lekas, M. Sibbald, K. Teichert-Kuliszewska, A. L. Klibanov, D. J. Stewart, and J. R. Lindner Therapeutic Arteriogenesis by Ultrasound-Mediated VEGF165 Plasmid Gene Delivery to Chronically Ischemic Skeletal Muscle Circ. Res., August 3, 2007; 101(3): 295 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Wu, F. M. Bengel, and S. S. Gambhir Cardiovascular Molecular Imaging Radiology, August 1, 2007; 244(2): 337 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Grote, G. Salguero, M. Ballmaier, M. Dangers, H. Drexler, and B. Schieffer The angiogenic factor CCN1 promotes adhesion and migration of circulating CD34+ progenitor cells: potential role in angiogenesis and endothelial regeneration Blood, August 1, 2007; 110(3): 877 - 885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Lu, X. Xu, M. Zhang, R. Cao, E. Brakenhielm, C. Li, H. Lin, G. Yao, H. Sun, L. Qi, et al. Combinatorial protein therapy of angiogenic and arteriogenic factors remarkably improves collaterogenesis and cardiac function in pigs PNAS, July 17, 2007; 104(29): 12140 - 12145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Vartanian and R. Sarkar Therapeutic Angiogenesis Vascular and Endovascular Surgery, July 1, 2007; 41(3): 173 - 185. [Abstract] [PDF]
|
|
|
|
|
|
L. Dirix, H Maes, and C Sweldens Treatment of arterial hypertension (AHT) associated with angiogenesis inhibitors Ann. Onc., June 1, 2007; 18(6): 1121 - 1122. [Full Text] [PDF]
|
|
|
|
|
|
V. van Weel, L. Seghers, M. R. de Vries, E. J. Kuiper, R. O. Schlingemann, I. M. Bajema, J. H.N. Lindeman, P. M. Delis-van Diemen, V. W.M. van Hinsbergh, J. H. van Bockel, et al. Expression of Vascular Endothelial Growth Factor, Stromal Cell-Derived Factor-1, and CXCR4 in Human Limb Muscle With Acute and Chronic Ischemia Arterioscler Thromb Vasc Biol, June 1, 2007; 27(6): 1426 - 1432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Saeed, D. Saloner, A. Martin, L. Do, O. Weber, P. C. Ursell, A. Jacquier, R. Lee, and C. B. Higgins Adeno-associated Viral Vector-Encoding Vascular Endothelial Growth Factor Gene: Effect on Cardiovascular MR Perfusion and Infarct Resorption Measurements in Swine Radiology, May 1, 2007; 243(2): 451 - 460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yla-Herttuala, T. T. Rissanen, I. Vajanto, and J. Hartikainen Vascular Endothelial Growth Factors: Biology and Current Status of Clinical Applications in Cardiovascular Medicine J. Am. Coll. Cardiol., March 13, 2007; 49(10): 1015 - 1026. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Rajagopalan, J. Olin, S. Deitcher, A. Pieczek, J. Laird, P. M. Grossman, C. K. Goldman, K. McEllin, R. Kelly, and N. Chronos Use of a Constitutively Active Hypoxia-Inducible Factor-1{alpha} Transgene as a Therapeutic Strategy in No-Option Critical Limb Ischemia Patients: Phase I Dose-Escalation Experience Circulation, March 13, 2007; 115(10): 1234 - 1243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Li, S. Hazarika, D. Xie, A. M. Pippen, C. D. Kontos, and B. H. Annex In Mice With Type 2 Diabetes, a Vascular Endothelial Growth Factor (VEGF)-Activating Transcription Factor Modulates VEGF Signaling and Induces Therapeutic Angiogenesis After Hindlimb Ischemia Diabetes, March 1, 2007; 56(3): 656 - 665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ye, H. Kh. Haider, S. Jiang, R. S. Tan, R. Ge, P. K. Law, and E. K.W. Sim Improved angiogenic response in pig heart following ischaemic injury using human skeletal myoblast simultaneously expressing VEGF165 and angiopoietin-1 Eur J Heart Fail, January 1, 2007; 9(1): 15 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Inoue, T. Kondo, K. Kobayashi, M. Aoki, Y. Numaguchi, M. Shibuya, and T. Murohara Therapeutic Angiogenesis Using Novel Vascular Endothelial Growth Factor-E/Human Placental Growth Factor Chimera Genes Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 99 - 105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-L. Ang, L. Takura Shenje, L. Srinivasan, and M. Galinanes Repair of the damaged heart by bone marrow cells: from experimental evidence to clinical hope. Ann. Thorac. Surg., October 1, 2006; 82(4): 1549 - 1558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Wang, R. Shamloul, X. Wang, Q. Meng, and L. Wu Sustained Normalization of High Blood Pressure in Spontaneously Hypertensive Rats by Implanted Hemin Pump Hypertension, October 1, 2006; 48(4): 685 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. W. Zhuang, L. Gao, M. Murakami, J. D. Pearlman, T. J. Sackett, M. Simons, and E. D. de Muinck Arteriogenesis: Noninvasive Quantification with Multi-Detector Row CT Angiography and Three-dimensional Volume Rendering in Rodents Radiology, September 1, 2006; 240(3): 698 - 707. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kobayashi, T. Kondo, N. Inoue, M. Aoki, M. Mizuno, K. Komori, J. Yoshida, and T. Murohara Combination of In Vivo Angiopoietin-1 Gene Transfer and Autologous Bone Marrow Cell Implantation for Functional Therapeutic Angiogenesis Arterioscler Thromb Vasc Biol, July 1, 2006; 26(7): 1465 - 1472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. van Weel, M. de Vries, P. J. Voshol, R. E. Verloop, P. H.C. Eilers, V. W.M. van Hinsbergh, J. H. van Bockel, and P. H.A. Quax Hypercholesterolemia Reduces Collateral Artery Growth More Dominantly Than Hyperglycemia or Insulin Resistance in Mice Arterioscler Thromb Vasc Biol, June 1, 2006; 26(6): 1383 - 1390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Semenza Therapeutic Angiogenesis: Another Passing Phase? Circ. Res., May 12, 2006; 98(9): 1115 - 1116. [Full Text] [PDF]
|
|
|
|
|
|
H. Iwama, S. Uemura, N. Naya, K.-i. Imagawa, Y. Takemoto, O. Asai, K. Onoue, S. Okayama, S. Somekawa, Y. Kida, et al. Cardiac Expression of Placental Growth Factor Predicts the Improvement of Chronic Phase Left Ventricular Function in Patients With Acute Myocardial Infarction J. Am. Coll. Cardiol., April 18, 2006; 47(8): 1559 - 1567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Veronese, A. Mosenkis, K. T. Flaherty, M. Gallagher, J. P. Stevenson, R. R. Townsend, and P. J. O'Dwyer Mechanisms of Hypertension Associated With BAY 43-9006 J. Clin. Oncol., March 20, 2006; 24(9): 1363 - 1369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Sica Angiogenesis Inhibitors and Hypertension: An Emerging Issue J. Clin. Oncol., March 20, 2006; 24(9): 1329 - 1331. [Full Text] [PDF]
|
|
|
|
 |
|
 Additional Information JAMA, March 15, 2006; 295(11): E1 - E6. [Full Text] [PDF]
|
|
|
|
|
|
Additional Information JAMA, March 15, 2006; 295(11): E7 - E14. [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Nordlie, L. E. Wold, B. Z. Simkhovich, C. Sesti, and R. A. Kloner Molecular Aspects of Ischemic Heart Disease: Ischemia/Reperfusion-Induced Genetic Changes and Potential Applications of Gene and RNA Interference Therapy Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2006; 11(1): 17 - 30. [Abstract] [PDF]
|
|
|
|
|
|
M. Boodhwani, Y. Nakai, S. Mieno, P. Voisine, C. Bianchi, E. G. Araujo, J. Feng, K. Michael, J. Li, and F. W. Sellke Hypercholesterolemia Impairs the Myocardial Angiogenic Response in a Swine Model of Chronic Ischemia: Role of Endostatin and Oxidative Stress Ann. Thorac. Surg., February 1, 2006; 81(2): 634 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. U. Lee, J. J. Wykrzykowska, and R. J. Laham Angiogenesis: Bench to Bedside, Have We Learned Anything? Toxicol Pathol, January 1, 2006; 34(1): 3 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hanif, A. Patel, and J. Dunning Might gene therapy offer symptomatic relief for patients with 'no option' angina? Interactive CardioVascular and Thoracic Surgery, December 1, 2005; 4(6): 627 - 632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Zbinden, R. Zbinden, P. Meier, S. Windecker, and C. Seiler Safety and Efficacy of Subcutaneous-Only Granulocyte-Macrophage Colony-Stimulating Factor for Collateral Growth Promotion in Patients With Coronary Artery Disease J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1636 - 1642. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dulak, S. P Schwarzacher, R. H Zwick, H. Alber, G. Millonig, C. Weiss, H. Hugel, M. Frick, A. Jozkowicz, O. Pachinger, et al. Effects of local gene transfer of VEGF on neointima formation after balloon injury in hypercholesterolemic rabbits Vascular Medicine, November 1, 2005; 10(4): 285 - 291. [Abstract] [PDF]
|
|
|
|
|
|
E. Toyota, D. C. Warltier, T. Brock, E. Ritman, C. Kolz, P. O'Malley, P. Rocic, M. Focardi, and W. M. Chilian Vascular Endothelial Growth Factor Is Required for Coronary Collateral Growth in the Rat Circulation, October 4, 2005; 112(14): 2108 - 2113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. H. Patel, H. Kimura, C. R. Weiss, G. L. Semenza, and L. V. Hofmann Constitutively active HIF-1{alpha} improves perfusion and arterial remodeling in an endovascular model of limb ischemia Cardiovasc Res, October 1, 2005; 68(1): 144 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Khurana, M. Simons, J. F. Martin, and I. C. Zachary Role of Angiogenesis in Cardiovascular Disease: A Critical Appraisal Circulation, September 20, 2005; 112(12): 1813 - 1824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Yoshida, K. Ohmori, H. Takeuchi, K. Shinomiya, T. Namba, I. Kondo, H. Kiyomoto, and M. Kohno Treatment of Ischemic Limbs Based on Local Recruitment of Vascular Endothelial Growth Factor-Producing Inflammatory Cells With Ultrasonic Microbubble Destruction J. Am. Coll. Cardiol., September 6, 2005; 46(5): 899 - 905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Tsutsumi and D. W. Losordo Double Face of VEGF Circulation, August 30, 2005; 112(9): 1248 - 1250. [Full Text] [PDF]
|
|
|
|
|
|
P. Leppanen, S. Koota, I. Kholova, J. Koponen, C. Fieber, U. Eriksson, K. Alitalo, and S. Yla-Herttuala Gene Transfers of Vascular Endothelial Growth Factor-A, Vascular Endothelial Growth Factor-B, Vascular Endothelial Growth Factor-C, and Vascular Endothelial Growth Factor-D Have No Effects on Atherosclerosis in Hypercholesterolemic Low-Density Lipoprotein-Receptor/Apolipoprotein B48-Deficient Mice Circulation, August 30, 2005; 112(9): 1347 - 1352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Hou, E. A.-S. Youssef, T. J. Brinton, P. Zhang, P. Rogers, E. T. Price, A. C. Yeung, B. H. Johnstone, P. G. Yock, and K. L. March Radiolabeled Cell Distribution After Intramyocardial, Intracoronary, and Interstitial Retrograde Coronary Venous Delivery: Implications for Current Clinical Trials Circulation, August 30, 2005; 112(9_suppl): I-150 - I-156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Voisine, J. Li, C. Bianchi, T. A. Khan, M. Ruel, S.-H. Xu, J. Feng, A. Rosinberg, T. Malik, Y. Nakai, et al. Effects of L-Arginine on Fibroblast Growth Factor 2-Induced Angiogenesis in a Model of Endothelial Dysfunction Circulation, August 30, 2005; 112(9_suppl): I-202 - I-207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Kano, Y. Morishita, C. Iwata, S. Iwasaka, T. Watabe, Y. Ouchi, K. Miyazono, and K. Miyazawa VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFR{beta} signaling J. Cell Sci., August 15, 2005; 118(16): 3759 - 3768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Laham, M. Post, M. Rezaee, L. Donnell-Fink, J. J. Wykrzykowska, S. U. Lee, D. S. Baim, and F. W. Sellke TRANSENDOCARDIAL AND TRANSEPICARDIAL INTRAMYOCARDIAL FIBROBLAST GROWTH FACTOR-2 ADMINISTRATION: MYOCARDIAL AND TISSUE DISTRIBUTION Drug Metab. Dispos., August 1, 2005; 33(8): 1101 - 1107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Heinl-Green, P. W. Radke, F. M. Munkonge, O. Frass, J. Zhu, K. Vincent, D. M. Geddes, and E. W.F.W. Alton The efficacy of a 'master switch gene' HIF-1{alpha} in a porcine model of chronic myocardial ischaemia Eur. Heart J., July 1, 2005; 26(13): 1327 - 1332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Voisine, C. Bianchi, T. A. Khan, M. Ruel, S.-H. Xu, J. Feng, J. Li, T. Malik, A. Rosinberg, and F. W. Sellke Normalization of coronary microvascular reactivity and improvement in myocardial perfusion by surgical vascular endothelial growth factor therapy combined with oral supplementation of L-arginine in a porcine model of endothelial dysfunction J. Thorac. Cardiovasc. Surg., June 1, 2005; 129(6): 1414 - 1420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Krombach, J. G. Pfeffer, S. Kinzel, M. Katoh, R. W. Gunther, and A. Buecker MR-guided Percutaneous Intramyocardial Injection with an MR-compatible Catheter: Feasibility and Changes in T1 Values after Injection of Extracellular Contrast Medium in Pigs Radiology, May 1, 2005; 235(2): 487 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Madeddu Therapeutic angiogenesis and vasculogenesis for tissue regeneration Exp Physiol, May 1, 2005; 90(3): 315 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Simons Angiogenesis: Where Do We Stand Now? Circulation, March 29, 2005; 111(12): 1556 - 1566. [Full Text] [PDF]
|
|
|
|
 |
|
 C. J Teng, K. Lachapelle, and R. C. Chiu Reappraisal of Recent Clinical Trials of Angiogenic Therapy in Myocardial Ischemia Asian Cardiovasc Thorac Ann, March 1, 2005; 13(1): 90 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Cao, A. Hong, H. Schulten, and M. J. Post Update on therapeutic neovascularization Cardiovasc Res, February 15, 2005; 65(3): 639 - 648. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. H. Annex and M. Simons Growth factor-induced therapeutic angiogenesis in the heart: protein therapy Cardiovasc Res, February 15, 2005; 65(3): 649 - 655. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Markkanen, T. T. Rissanen, A. Kivela, and S. Yla-Herttuala Growth factor-induced therapeutic angiogenesis and arteriogenesis in the heart-gene therapy Cardiovasc Res, February 15, 2005; 65(3): 656 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Rodriguez, B. Nespereira, M. Perez-Ilzarbe, E. Eguinoa, and J. A. Paramo Vitamins C and E prevent endothelial VEGF and VEGFR-2 overexpression induced by porcine hypercholesterolemic LDL Cardiovasc Res, February 15, 2005; 65(3): 665 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wang, E. Kilic, U. Kilic, B. Weber, C. L. Bassetti, H. H. Marti, and D. M. Hermann VEGF overexpression induces post-ischaemic neuroprotection, but facilitates haemodynamic steal phenomena Brain, January 1, 2005; 128(1): 52 - 63. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Dai, J. Huang, B. Klitzman, C. Dong, P. J. Goldschmidt-Clermont, K. L. March, J. Rokovich, B. Johnstone, E. J. Rebar, S. K. Spratt, et al. Engineered Zinc Finger-Activating Vascular Endothelial Growth Factor Transcription Factor Plasmid DNA Induces Therapeutic Angiogenesis in Rabbits With Hindlimb Ischemia Circulation, October 19, 2004; 110(16): 2467 - 2475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ohtani, K. Egashira, K.-i. Hiasa, Q. Zhao, S. Kitamoto, M. Ishibashi, M. Usui, S. Inoue, Y. Yonemitsu, K. Sueishi, et al. Blockade of Vascular Endothelial Growth Factor Suppresses Experimental Restenosis After Intraluminal Injury by Inhibiting Recruitment of Monocyte Lineage Cells Circulation, October 19, 2004; 110(16): 2444 - 2452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jacobi, B. Y.Y. Tam, G. Wu, J. Hoffman, J. P. Cooke, and C. J. Kuo Adenoviral Gene Transfer With Soluble Vascular Endothelial Growth Factor Receptors Impairs Angiogenesis and Perfusion in a Murine Model of Hindlimb Ischemia Circulation, October 19, 2004; 110(16): 2424 - 2429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. H. Yang, G. W. Barsness, B. J. Gersh, K. Chandrasekaran, and A. Lerman Current and Future Treatment Strategies for Refractory Angina Mayo Clin. Proc., October 1, 2004; 79(10): 1284 - 1292. [Abstract] [PDF]
|
|
|
|
|
|
M. Heil and W. Schaper Influence of Mechanical, Cellular, and Molecular Factors on Collateral Artery Growth (Arteriogenesis) Circ. Res., September 3, 2004; 95(5): 449 - 458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.L Grines The AGENT clinical trials programme Eur. Heart J. Suppl., September 1, 2004; 6(suppl_E): E18 - E23. [Abstract] [Full Text]
|
|
|
|
|
|
B. Sivakumar, L. E. Harry, and E. M. Paleolog Modulating Angiogenesis: More vs Less JAMA, August 25, 2004; 292(8): 972 - 977. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. F. Zhou, E. Stabile, J. Walker, M. Shou, R. Baffour, Z. Yu, D. Rott, G. D. Yancopoulos, J. S. Rudge, and S. E. Epstein Effects of gene delivery on collateral development in chronic hypoperfusion: Diverse effects of angiopoietin-1 versus vascular endothelial growth factor J. Am. Coll. Cardiol., August 18, 2004; 44(4): 897 - 903. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||